TD Cowen reiterates Cencora stock Buy rating on generics thesis By Investing.com

Cencora reported Q2 fiscal 2026 EPS of $4.75 versus $4.83 expected and revenue of $78.4B versus $80.97B expected, a clear miss on both lines. Management lowered U.S. healthcare revenue guidance but kept U.S. healthcare adjusted operating income guidance unchanged, while TD Cowen reiterated a Buy and $400 price target despite near-term deceleration concerns. Shares trade at $262.70, near the 52-week low of $244.82, after falling 14% over the past week.

Analysis

The market is treating this as a single-quarter miss, but the more important signal is that the earnings power thesis is now being challenged at the segment level, not just on timing. For a distributor, that matters because the bull case depends on operating leverage compounding through steady utilization; when core growth decelerates, the market starts discounting not just the current year but the durability of margin expansion two to four quarters out. That is why the de-rating can persist even if management keeps full-year profit guidance intact.

The second-order effect is on the pharmacy-services ecosystem: if Cencora is seeing slower healthcare momentum, the pressure likely ripples into generics, biosimilars, and specialty workflow partners that depend on consistent throughput. In the near term, weaker confidence in the back-half ramp can also push customers and suppliers to negotiate harder on contract terms, which can suppress gross profit per unit even if volume normalizes later. Competitors with more mix toward specialty or international exposure should be relatively insulated versus peers tied to U.S. healthcare distribution volumes.

The setup is attractive only if you believe the market is overshooting on a one-quarter reset. At roughly 14x calendar 2027 earnings, the stock is pricing in a multi-quarter growth stall; if growth merely re-accelerates modestly over the next two earnings prints, the downside should compress quickly. The risk is that this is not a timing issue but an underwriting issue—if the second half fails to show clear acceleration, the multiple can stay suppressed for months, especially with an oversold technical backdrop that can still overshoot on any additional negative revision.

Contrarian view: this may be less a broken thesis than a classic distributor digestion phase after a period of unusually easy comparisons. If management can stabilize U.S. healthcare revenue while protecting operating income, the market may eventually re-rate the name on earnings power rather than growth optics. But until there is evidence of inflection, the path of least resistance is still lower, because investors will demand proof before paying for the long-duration biosimilar/generics story again.

Key Decisions for Investors

• Stay tactical: avoid adding to COR outright until the next earnings update or monthly operating commentary confirms back-half acceleration; downside could persist for 1-2 quarters if guidance cadence remains soft.
• For higher-conviction accounts, consider a small starter long COR only on confirmation of stabilization, targeting a 12-18 month re-rate toward the low-to-mid $300s; risk/reward is favorable only if the next print removes guidance uncertainty.
• Pair trade: long the higher-quality healthcare distributor / specialty exposure vs short COR to isolate idiosyncratic U.S. healthcare volume risk; this should work over the next 1-3 months if revisions continue to drift lower.
• Use COR as a mean-reversion candidate for options only: sell cash-secured puts 10-15% below spot into elevated implied volatility, with the view that the market has already discounted a lot of bad news but may need time to validate a floor.